Last Wednesday, diabetes researchers and advocates from around the country convened in Washington, DC, for an FDA hearing on the Artificial Pancreas with the aim of making this pipe dream a reality. The point of the hearing was to allow JDRF and other stakeholders — researchers, industry reps, and patients — a chance to provide input on the Artificial Pancreas Project, in particular “recommendations to ensure the safe and effective testing of artificial pancreas technology…Read more »
Today, just a sampling of some of the interesting stuff presented at last week’s Diabetes Technology Society meeting, that will be out on the market in … um… some years from now (?):
IN-105 Oral Insulin for Type 2 diabetes – Biocon Limited, apparently India’s premier biotechnology company, has been developing oral insulin tablets for some years now. Positive research results were announced last year. And they’re not just for basal use, either. Studies confirmed…Read more »
The Diabetes Technology Society held its annual meeting last Thursday through Saturday, which always takes place just about a mile and a half from my house. But guess what? This was the very first year that I found myself on the inside of this exclusive event, participating in a panel (the very last panel of the 3-day event) on “technologies to drive patient adherence.”
The term “adherence” made me bristle, too, because it sounds like…
On Wednesday of this week, the eighth annual Diabetes Technology Meeting convenes in Bethesda, MD, for a three-day event (spanning this year’s World Diabetes Day on Thursday) that will survey the latest technological advances for people with diabetes. How I’d love to be a fly on the wall at that conference!
Nevermind that I’ve been trying to gain press access to this meeting for at least the last 3 years; I have a mole this…